Published in Blood Weekly, March 29th, 2001
Although many researchers suspect that early dose intensification should produce better results than late intensification, the reports from "randomized trials comparing standard- and high-dose chemotherapy with ASCT [autologous stem cell transplantation] are still controversial," according to Andreas Schneeweiss and colleagues.
Despite improving initial complete remission (CR) rates, Schneeweiss et al. found that double- and triple-dose HDCT (D- and T-HDCT) had no significant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.